Thiol switches are important regulators of cellular signaling and are coordinated by several redox enzyme systems including thioredoxins, peroxiredoxins, and glutathione. Thioredoxin-1 (Trx1), in particular, is an important signaling molecule not only in response to redox perturbations, but also in cellular growth, regulation of gene expression, and apoptosis. The active site of this enzyme is a highly conserved C-G-P-C motif and the redox mechanism of Trx1 is rapid which presents a challenge in determining specific substrates. Numerous in vitro approaches have identified Trx1dependent thiol switches; however, these findings may not be physiologically relevant and little is known about Trx1 interactions in vivo. In order to identify Trx1 targets in vivo, we generated a transgenic mouse with inducible expression of a mutant Trx1 transgene to stabilize intermolecular disulfides with protein substrates. Expression of the Trx1 "substrate trap" transgene did not interfere with endogenous thioredoxin or glutathione systems in brain, heart, lung, liver, and kidney. Following immunoprecipitation and proteomic analysis, we identified 41 homeostatic Trx1 interactions in perinatal lung, including previously described Trx1 substrates such as members of the peroxiredoxin family and collapsin response mediator protein 2. Using perinatal hyperoxia as a model of oxidative injury, we found 17 oxygen-induced interactions which included several cytoskeletal proteins which may be important to alveolar development. The data herein validates this novel mouse model for identification of tissue-and cell-specific Trx1-dependent pathways that regulate physiological signals in response to redox perturbations.
INTRODUCTION
Thiol switches, much like phosphorylation of serine, threonine, and tyrosine, regulate protein activity through a variety of oxidative cysteine modifications in response to intracellular and environmental signals. Thioredoxin-1 (Trx1), a fundamental oxidoreductase, is essential for cell growth and survival as deletion of this enzyme is embryonic lethal [1] . The redox action of Trx1 belies its function, a general antioxidant that maintains redox homeostasis in cellular compartments. However, Trx1 is also an important regulator of thiol switches, which indicates that it has the capacity to regulate signaling responses. Within its active site are two vicinal cysteines (Cys32/35) that lie in a cysteineglycine-proline-cysteine orientation [2] . This "thioredoxin fold" is highly conserved throughout organismal taxa, from E. coli to modern humans [3] . The crystal structure of Trx1, resolved in the 1970s, demonstrated that the thioredoxin fold contains five pleated sheets in parallel and antiparallel orientation which are surrounded by four alpha-helices [4] . Additional crystallography studies have shown that Trx1 undergoes a conformation change when the reactive cysteines are oxidized [5] . It is the cyclical oxidation and reduction of vicinal thiols in the Trx1 active site which gives this enzyme its oxidoreductase activity. This mechanism is responsible for its intermolecular interactions with other dedicated redox cycling enzymes as well as protein substrates containing thiol switches [6] . Trx1 reduces oxidized cysteines, including disulfide bridges, in target substrates. The Cys32 residue, through nucleophilic attack, binds to the target substrate. Cys35 then reduces this bond which creates a disulfide bridge between the two cysteines within the active site of Trx1. This effectively inhibits the reducing activity of Trx1. Trx1 activity is restored when it is reduced by its partner enzyme, thioredoxin reductase-1 (TrxR1) [7] . This reaction mechanism is rapid which presents a challenge when studying Trx1 interactions both in vitro and in vivo.
One method that has been essential for elucidating novel Trx1 substrates is the use of Isotope-Coded Affinity Tags (ICAT). This method was first developed using protein lysates from fertilized barley seeds [8] . Iodoacetamide was used to block free thiols generated by Trx1-dependent reduction of disulfides in target proteins. "Light" and "heavy" carbon ICAT reagents were added to the control and experimental samples, respectively, which allowed for the measurement of Trx1-dependent reduction based upon the ratio of light to heavy ICAT carbon (control vs. experimental) via liquid chromatography-mass spectrometry. The ICAT method has also been applied to additional models, including eukaryotic cells [9] and ventricle tissue from mice with cardiac-specific overexpression of Trx1 [10] . This method has as a distinct advantage in that not only can Trx1-dependent disulfide reduction of target substrates can be measured, but additional posttranslational modifications, such as nitrosylation by Trx1, can also be assessed [11] . However, while Trx1 substrates have been identified using ICAT, these interactions were found in vitro and may not have biological relevance.
The Trx1 substrate trap is a bona fide method to directly identify Trx1 interactions ( Figure  1 ) [12] . For human Trx1, mutation of Cys35 to serine (C35S) replaces the highly reactive resolving thiol with a hydroxyl group thereby interrupting the oxidoreductase reaction. Therefore, the substrate trap mutation stabilizes the intermolecular disulfide between Trx1 and substrate. The Trx1 substrate trap, including variations utilizing an alanine substitution, has been used in a variety of systems to identify Trx1-dependent thiol switches. This approach identified targets of the thioredoxin-related protein DsbG in E. coli [13] and Trx1:peroxiredoxin complexes in yeast [14] . It has also been used with plant-derived recombinant thioredoxin in a test tube-based system [15, 16] . Studies from our laboratory have successfully used the Trx1 substrate trap in lung adenocarcinoma cells [17] . Novel nuclear targets, such as the transcription factor PC4 and SFRS1 interaction protein 1 (PSIP1), have been identified by fusing a canonical nuclear localization signal to the substrate trap transgene [18] . However, there are caveats with using this substrate trap in vitro or in cellular models since they do not recapitulate complex physiologies of multicellular organisms. Additionally, immortalized tumor cell lines or primary cells requiring extensive manipulations during isolation do not likely represent physiological conditions and may harbor redox perturbations [19, 20] . While results from these studies have expanded our knowledge of the interactions of Trx1, we are still lacking information on interactions of this important redox enzyme in vivo.
We have generated a transgenic mouse that expresses the human Trx1 C35S substrate trap with an N-terminal flag tag (flag-hTrx1 C35S ). This transgene also includes a loxP-STOP-loxP cassette between the CMV early enhancer/chicken β-actin (CAG) promoter and the flag-hTrx1 C35S sequence which allows for spatial and temporal transgene expression. In this study, flag-hTrx1 C35S was ubiquitously expressed using cre recombinase driven by the βactin promoter (actin-cre) [21] . 41 static interactions of Trx1 were identified in postnatal lung tissue, including six known substrates. With the addition of neonatal hyperoxic injury as an oxidative injury paradigm, we identified 17 oxygen-sensitive Trx1 substrates. Combined with different disease models, temporal and cell-specific expression of flag-hTrx1 C35S in this novel transgenic mouse will serve as an essential tool to elucidate redoxdependent Trx1 signaling in variety of tissues and disease pathologies.
was created by knocking in three tandem attP sites into the Rosa26 locus in an FVB mouse. Second, the flag-hTrx1 C35S transgene was inserted into the Rosa36-3attP site. The integration cocktail, which consisted of the plasmid pBT378-attP-flag-hTrx1 C35S -attP and in vitro transcribed ϕC31 mRNA, was injected into the pronucleus of zygotes from heterozygous Rosa26-3attP FVB mice. The ϕC31 enzyme ensured the correct integration of the flag-hTrx1 C35S transgene into the 3attP locus. Third, zygotes were implanted into CD1 foster mice. Fourth, two founders were identified by PCR. FVB flag-hTrx1 C35S mice were crossed with C57Bl6/J mice to create generation N1. Genomic DNA was prepared from tail biopsy and genotyping was performed using the AccuStart II Mouse Genotyping Kit (Quanta Biosciences, Gaithersburg, MD) and two primer sets: 1) CAG promoter 5'-GGTGATAGGTGGCAAGTGGTATTCCGTAAG-3', 5'-CATATATGGGCTATGAACTAATGACCCCGT-3' and 2) Poly-A tail 5'-GACGATGTAGGTCACGGTCTCGAAG-3', 5'-CCGCGAAGTTCCTATACCTTTTG-3'. N1 FVB/C57Bl6/J flag-hTrx C35S hemizygous mice were paired with actin-cre homozygous mice obtained from The Jackson Laboratory (Bar Harbor, ME). Offspring from these breeders were sacrificed for tissue collection between postnatal days 5 and 7 (PND5-7).
Hyperoxia Treatment
All animal experiments were conducted with approval from the Sanford Research Institutional Animal Care and Use Committee. Sanford Research has an Animal Welfare Assurance on file with the Office of Laboratory Animal Welfare (A-4568-01) and is a licensed research facility under the authority of the United Sates Department of Agriculture (46-R-0011). Actin-cre;flag-hTrx1 C35S and actin-cre newborn mice litters (PND<0.5) were randomly placed in 85% oxygen or room air the first seven days of life [23] . Oxygen concentration was monitored and delivered using a ProOx110 controller (Biospherix, Parish, NY). Dams were rotated between hyperoxia and room air every 24 hours to prevent maternal lung injury. After seven days, pups were sacrificed by quick decapitation and lung tissue was snap frozen and stored at −80°C until analyzed.
Protein Isolation, SDS-PAGE & Western Blot
Snap-frozen tissue was thawed in protein lysis buffer (50 mM Tris, pH 7.4; 150 mM NaCl, 10% Triton X-100, 10% NP-40) supplemented with 1% protease inhibitor cocktail (Sigma Aldrich, St. Louis, MO) and 0.1 mM PMSF. Tissue was homogenized, incubated on ice for 30 minutes, and then centrifuged at 10,000 rpm for 15 minutes at 4°C. Supernatants were collected and protein concentration was determined by BCA (Thermo Fisher Scientific, Waltham, MA). Samples were diluted in 2xLaemmli's buffer, separated on 15% SDS-PAGE gels, and proteins were transferred to PVDF membranes using Bio-Rad Trans-Blot Turbo Transfer System (Hercules, CA). Membranes were blocked in 5% milk for one hour and then probed with anti-thioredoxin-1 (Cell Signaling, Danvers, MA), anti-flag (Sigma Aldrich), anti-thioredoxin reductase-1 (Abcam, Cambridge, MA) or anti-actin (Sigma Aldrich) primary antibodies overnight at 4°C. Membranes were washed 3 times in TBS/ Tween-20 for 5 minutes each then incubated with HRP-conjugated goat anti-rabbit ormouse (Southern Biotech, Birmingham, AL) secondary antibodies for 1 hour. Bands were detected by chemiluminescence and images were captured on a UVP bioimaging system (Upland, CA).
Immunohistochemistry
Tissues were fixed in 10% neutral buffered formalin and processed on a Leica 300 ASP tissue processor. The paraffin embedded tissues were sectioned at 5 µm. The BenchMark ® XT automated slide staining system (Ventana Medical Systems, Inc., Tucson, AZ) was used for the antibody optimization and staining. The Ventana iView DAB detection kit was used as the chromogen and the slides were counterstained with hematoxylin. Omission of the primary antibody served as the negative control. Anti-thioredoxin-1 primary antibody (Cell Signaling) was used at a dilution of 1:200.
Recombinant Protein Expression
hTrx1 wild-type, hTrx1 C32S , hTrx1 C35S , and hTrx1 C32,35S sequences were cloned into the pGEX-2TK-GST plasmid (GE Healthcare, Little Chalfont, United Kingdom) and transformed into BL21(DE3)pLysS E. coli. The cells were grown in 2xYTA medium (yeast extract, tryptone, NaCl, 100 ug/mL ampicillin) and expression of the GST-tagged hTrx proteins was induced with 0.1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) (Thermo Scientific). After four hours incubation with IPTG, the bacteria were pelleted by centrifugation for 10 minutes at 4°C at 7700×g. Once the supernatant was removed, the bacterial cell pellet was lysed with 4 mL BPER Bacterial Protein Reagent (Thermo Scientific) per gram of cell pellet supplemented with lysozyme, DNAse 1, EDTA-free protease inhibitors, and PMSF. The sample was incubated for 15 minutes at room temperature, and then spun at 15,000×g for 15 minutes at 4°C. The supernatant was then purified using a GST Spin Purification Kit (Pierce) according to the manufacturer's directions. Elution of the hTrx1 proteins was done by thrombin cleavage. After the addition of the supernatant to the column and the washing steps, columns were incubated overnight in thrombin cleavage buffer (100 U Thrombin; MP Biomedicals, Santa Ana, CA) in phosphate buffered saline. Recombinant hTrx1 proteins were then eluted with the elution buffer from the purification kit and desalted using Zeba Spin Desalting columns (Thermo Scientific). Total protein concentration was determined by BCA. For Trx1 activity assays, lysates were diluted in activity assay buffer (see below) for input directly into the assay. For Western blot, lysates were diluted in Laemmle's buffer prior to loading on SDS-PAGE gels.
Trx1/TrxR1 Activity Assay
Activities of thioredoxin-1 and thioredoxin reductase-1 were measured using a standard insulin reduction assay (IMCO, Stockholm, Sweden). Snap-frozen tissue was thawed in activity assay buffer (1 mM NaHPO 4 anhydrous, 5 mM EDTA pH 8.0) supplemented with 1% protease inhibitor cocktail (Sigma Aldrich), 1% phosphatase inhibitor cocktails 2 and 3 (Sigma Aldrich) and 0.1 mM PMSF. Tissues were homogenized, incubated for 30 minutes on ice and then spun at 10,000 rpm for 15 minutes at 4°C. Supernatants were collected and protein concentration was determined by BCA. Trx1 and TrxR1 activity was analyzed according to the manufacturer's directions.
GSH:GSSG Measurements
Sample derivatization for HPLC was performed as described previously by Jones [24] and modified by Harris and Hansen [25] . Briefly, lung tissue was snap frozen in 5% perchloric acid supplemented with 10 µM gamma-glutamylglutamate. Once thawed, tissue was ultrasonicated then centrifuged at 14000 g for 10 minutes. The supernatant was set aside and the pellet was solubilized in 100 mM sodium hydroxide. Protein concentration was determined by BCA assay. Iodoacetic acid (14.8 mg/mL) was added to the supernatant to block free thiols, the pH was adjusted to 9.0 with saturated potassium tetraborate, and incubated for 20 minutes. Amino groups were labels with dansyl chloride (20 mg/mL) and the lung lysates were incubated at room temperature in the dark overnight. Derivatization was completed by adding 500 µL chloroform followed by vortexing and centrifugation. GSH and GSSG concentrations were resolved and quantified using reverse-phase HPLC (Waters 2695 Alliance Separations Module with a Supelcosil LC-NH 2 column). Detection of peaks was made using a Waters 2474 fluorescence detector (335 nm/518 nm). Molarity values of GSH and GSSG were determined through standardization with the internal standard (gamma-glutamylglutamate) and sample protein concentrations. Redox potentials were calculated using the Nernst equation [26] .
Immunoprecipitation and Mass Spectrometry
Frozen lung tissue was thawed in non-denaturing IP-Lysis Buffer (1 M Tris HCl pH7.4, 5 M NaCl, 0.5 mM EDTA pH 8.0, 1% protease inhibitor, phosphatase inhibitor cocktails 2 and 3, 0.1 mM PMSF, 5 mM iodoacetic acid). Tissue was homogenized, incubated at 4°C on a rotator for 2 hours, and then centrifuged at 12,000 rpm for 20 minutes at 4°C. Supernatants were collected and protein concentration was determined by BCA. 800 µg of lung lysate was added to 50 µL of anti-flag M2 magnetic beads (Sigma Aldrich). The sample:bead mixture was rotated overnight at 4°C. After washing five times with 1×TBS, proteins were eluted from the beads in 50 µL 2xLaemlli's buffer (Biorad) by boiling. Lung eluates were pooled by eluting into the same 50 µL of 2xLaemlli's. 40 µL of the eluate was run on a Mini-PROTEAN TGX gradient (8-16%) precast gel (Biorad, Hercules, CA) and bands were detected by silver stain for mass spectrometry (Thermo Fisher Scientific). IgG bands were excised and the gels were destained according to the manufacturer's directions. Samples were analyzed by LC-MS/MS using a LTQ Orbitrap Velos mass spectrometer (Thermo Fisher Scientific). Peptides were analyzed using Sequest (Thermo Fisher Scientific; version 1.3.0.339). Sequest was set up to search assuming the digestion enzyme trypsin. Sequest was searched with a fragment ion mass tolerance of 0.80 Da and a parent ion tolerance of 10.0 PPM. Oxidation of methionine and carbamidomethyl of cysteine were specified in Sequest as variable modifications. Scaffold (version Scaffold_4.4.6, Proteome Software Inc., Portland, OR) was used to validate MS/MS based peptide and protein identifications. Peptide identifications were accepted if they could be established at greater than 12.0% probability to achieve a false discovery rate (FDR) less than 0.1% by the Scaffold Local FDR algorithm. Protein identifications were accepted if they (i) could be established at greater than 99.0% probability, (ii) contained at least 2 unique peptides, and (iii) were not detected in control samples. Protein probabilities were assigned by the Protein Prophet algorithm [27] . Proteins that contained similar peptides and could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles of parsimony. Proteins sharing significant peptide evidence were grouped into clusters. Mass spectrometry data was visualized in Scaffold 4 and highlighted results were chosen based on unique peptides found only in the samples from the thioredoxin substrate mouse.
Statistical Analyses
Values represent mean ± standard deviation of biological replicates. The Student's t-test was used to determine significance using GraphPad Prism 5 (GraphPad Software, La Jolla, CA). Statistical significance was defined as p≤0.05.
RESULTS

Cre-inducible expression of flag-hTrx1 C35S
The flag-hTrx1 C35S gene was successfully inserted into the genome of the Rosa26-3attP founder (Figure 2A ). Both the CAG-promoter and the poly-A tail portion of the transgene were detected by PCR ( Figure 2B ). The inclusion of the loxP-stop-loxP sequence was incorporated into the flag-hTrx1 C35S mice for spatial and temporal regulation of the substrate trap. Mouse embryonic fibroblasts derived from flag-hTrx1 C35S mice displayed dose-dependent expression of the transgene through induction with recombinant tat-cre (data not shown). For this study, we obtained global expression of the transgene in all tissues by generating the actin-cre;flag-hTrx1 C35S mice with ubiquitous expression of cre recombinase ( Figure 3A) . Expression of flag-hTrx1 C35S was only observed in actin-cre;flag-hTrx1 C35S tissues and not the actin-cre controls ( Figure 3B ). This was evidenced by the hTrx1 doublet as the flag epitope adds approximately 6 kDa to hTrx1. Expression of flag-hTrx1 C35S did not alter the levels of endogenous mouse Trx1 or its corresponding reductase, TrxR1 ( Figure  3B ). The expression pattern of the flag-hTrx1 C35S was corroborated in the major tissues using immunochemistry ( Figure 3C ). Unlike in the actin-cre controls which have defined, localized expression of endogenous Trx1, actin-cre;flag-hTrx1 C35S mice had robust transgene expression in brain, lung, heart, liver, and kidney. Taken together, these results illustrate that flag-hTrx C35S was successfully expressed in viable offspring. hTrx1 C35S expression does not disrupt endogenous thioredoxin and glutathione systems. Recent work has indicated that overexpression of mutant hTrx1 in mice effects the expression of the endogenous mouse Trx1. Constitutive overexpression of a catalytic-dead hTrx1 mutant severely inhibited endogenous Trx1 activity in mice [28] . Although expression of flag-hTrx1 C35S did not affect expression of endogenous Trx1 ( Figure 3B ), we tested if the substrate trap transgene exerted dominant-negative effects on endogenous Trx1 activity. First, we measured the activity of several recombinant hTrx1 mutations to demonstrate that the C35S mutation did not exhibit oxidoreductase activity. Recombinant hTrx1 wild-type as well as hTrx1 C32S , hTrx1 C35S , and hTrx1 C32,35S were generated using a bacterial expression system ( Figure 4A ). Wild-type Trx1 had a dose-dependent increase in Trx activity ( Figure  4B ). Mutation of either the attacking (C32S) or resolving (C35S) cysteine abolished activity ( Figure 4B ). This confirms that hTrx1 C35S does not display any oxidoreductase activity.
Second, we collected samples from actin-cre;flag-hTrx1 C35S mice for Trx1 activity assays. In these mice, the activity of endogenous Trx1 and its reductase, TrxR1, was unchanged compared to actin-cre control mice ( Figure 5A,B) . It was also important to determine if expression of flag-hTrx1 C35S had any effects on the glutathione system which is also responsible for cellular redox homeostasis. While there was slight but not significant oxidation of glutathione (GSSG) in the liver, there was no measurable oxidation of glutathione in all other tissues ( Figure 5C,D) . Furthermore, flag-hTrx1 C35S expression did not alter glutathione redox potential (GSH/GSSG E h ) ( Figure 5E ). These data demonstrate that flag-hTrx1 C35S transgene expression does not affect endogenous redox circuitry systems.
Identification of Trx1 disulfide targets in vivo
Immunoprecipitation experiments were performed using lung tissue collected from actincre; flag-hTrx1 C35S mice and actin-cre controls. To identify Trx1 interactions occurring in lung under homeostatic conditions, immunoprecipitations were performed with eight mouse tissues (four per group). The four eluate samples were pooled by boiling, in succession, in the same Laemmli's buffer. This strategy was used in order to ensure equal contributions from multiple mice as well as to minimize sample-sample variations and detection of falsepositives. For hyperoxia-induced interactions, mice were maintained in 85% oxygen for the first seven days of life and lung tissues were treated in the same manner. Flag-hTrx1 C35S :substrate complexes were captured using paramagnetic beads conjugated to antiflag antibodies. The input sample (unprocessed lung lysate), as well as the eluate, which was collected by boiling the beads in Laemmli's buffer, were separated by SDS-PAGE and subjected to silver stain ( Figure 6A ). The expression and purification of flag-hTrx1 C35S was detected in actin-cre;flag-hTrx1 C35S lung eluates via Western blot, both with anti-Trx1 and anti-flag antibodies (Figure 6B,C) . For the gels which were silver stained, the eluate samples were collected for mass spectrometry ( Figure 6A ). (Tables 1 and 2 ). For the homeostatic interactions, the flag-hTrx1 C35S transgene and several known Trx1 substrates, peroxiredoxin 1 (Prxn1), peroxiredoxin 5 (Prxn5), peroxiredoxin 2 (Prxn2) and collapsin response mediator protein 2 (Crmp2) were present. Actin-cre;flag-hTrx1 C35S mice, and corresponding littermate controls, were challenged using a well characterized oxygen exposure model which recapitulates the premature infant lung disease bronchopulmonary dysplasia [29] . It has been previously shown that hyperoxia treatment in mice oxidizes Trx1, but does not change its expression [30] . Alterations of Trx1 activity as well as expression have been associated with oxygen-induced pathologies, including bronchopulmonary dysplasia (BPD) and asthma [31] . In response to hyperoxia, several new oxygen-dependent Trx1 interactions were detected ( Table 2 ). Of particular interest are several cytoskeleton interacting proteins including capping protein (actin filament) muscle Z-line, beta, isoform CRA (Capzb), band 3 anion transport protein (alc4a1) carbonic anhydrase 2 (CA2), guanine nucleotide-binding protein subunits beta-2-like1 (Gnb1l1), and tubulin beta-4B chain (Tubb4b) because of their possible involvement in alveolar development and injury. These data establish the functionality of the Trx1 substrate trap in vivo and demonstrate how this approach can be used to identify redox-dependent Trx1 signaling pathways in the pathogenesis of oxidative diseases.
Mass spectrometry identified 41 static interactions and 17 hyperoxia-induced interactions of Trx1
DISCUSSION
Reversible oxidation of thiol switches is a mechanism to regulate activities of non-redox proteins. This notion has been supported by (i) cysteine conservation across organisms, (ii) high cysteine reactivity under biological conditions, (iii) and frequent location of cysteines adjacent to functional sites [32] [33] [34] . Oxidation and reduction of cysteines creates a mechanism by which protein activity can be controlled through activities of cysteinerecognizing redox enzymes. This group of proteins includes the thioredoxin-and glutathione-dependent enzyme systems. In addition to serving an antioxidant capacity, Trx1 has been recognized as an important regulator of thiol switches and plays a direct role in controlling intracellular and extracellular signaling, regulation of gene expression, growth and proliferation, and metabolism [31] . Trx1 also functions to control protein folding [35] , denitrosylation [36] , and reduction of sulfhydration and sulfenic acid [37, 38] . Trx1 regulation of cysteine redox status is an important mechanism to promote sensing and adaptation environmental oxidants via the activities of thiol switches.
A technical challenge when identifying functional thiol switches is the rapid nature by which redox reactions occur. ICAT with addition of HPDP-biotin has been instrumental in identifying Trx1-dependent denitrosylation of substrates [39] . In a neuroblastoma cell line, ICAT was successfully used to identify peroxiredoxin 1 (Prxn1), cyclophilin A, and cofilin-1, as well as several ribosomal proteins and elongation factors, whose nitrosylation status is controlled by Trx1 [9] . Samples derived from mouse cardiac tissue, have identified several Trx1 targets, including metabolic enzymes such as glyceraldehyde-3-phosphate dehydrogenase and fatty acid-binding protein [10] . The major drawback to the ICAT technique is that it only measures indirect Trx1 interactions in sample lysates. Unlike the ICAT method, the thioredoxin substrate trap assesses direct Trx1 interactions in intact biological systems. Endogenous expression of a Trx1 protein where the Cys35 residue is mutated to serine creates a stable intermediate between thioredoxin and its substrate and these complexes are then analyzed with mass spectrometry. We have successfully used this technique for proteomic identification of novel Trx1 substrates in lung adenocarcinoma cells [17] . We have taken this method one step further and created a novel transgenic mouse model that expresses the Trx1 substrate trap. With this model, we have identified known and novel static and hyperoxia-induced interactions of Trx1 which are potential thiol switches in vivo.
Homeostatic Trx1 Interactions
We identified several known and novel Trx1 substrates in lungs of actin-cre;flag-hTrx1 C35S mice. Of the five members of the peroxiredoxin family known to interact with Trx1, Prxn1, Prxn2, and Prxn5 were identified by mass spectrometry. Peroxiredoxins and thioredoxins are known to coordinate oxidation and reduction of thiol switches respectively. For example, Prxn2 was recently shown to transmit oxidizing equivalents of hydrogen peroxide to STAT3 which is then reduced by Trx1 [40] . We also identified 14-3-3 protein theta and 40S ribosomal protein 11 which have been show to interact with Trx1 [9, 41] . Of particular interest is a known target of Trx1 that was determined by mass spectrometry, collapsin response mediator protein 2 (Crmp2). Crmp2 has five phosphorylation sites (Tyr479, Thr509/514/555, Ser522), as well as undergoes SUMOylation at Lys374 and reversible oxidation at Cys504, all of which have been shown to alter the function of this protein [42] [43] [44] . Interestingly, all the aforementioned posttranslational modifications reside in the same region of the protein, suggesting a correlation between redox, phosphorylation, and SUMOylation modifications in the regulation of Crmp2 function. For example, the oxidation status of Cys504 defines two conformations of the Crmp2 complex and accumulation of oxidized Crmp2 correlates with neurite outgrowth [45] . Crmp2 reduction leads to the more open Crmp2 complex conformation with greater exposure of hydrophobic regions which interact with subsequent effector molecules such as kinases or phosphatases [45] . Interestingly, the Trx1:Crmp2 interaction was mapped to the Cys504 residue of Crmp2, suggesting that Trx1 is an important determinant of Crmp2 posttranslational modifications and function [46] . Although Crmp2 has been primarily associated with neurological diseases including Alzheimer's and schizophrenia [47] [48] [49] [50] , Crmp2 is highly expressed in lung tissue as well as lung tumor cells [51] . Although endogenous function of Crmp2 in the lung remains unknown, differential Crmp2 posttranslational modifications are associated with nonsmall cell lung cancer [52] . The detection of known Trx1 substrates in this transgenic mouse model demonstrates the functionality of our Trx1 substrate trap mouse and our results are the first evidence that Trx1 interacts with Crmp2 in the lung in vivo.
We also identified several novel substrates of Trx1 which have direct relevance to lung function and disease: collapsin response mediator protein 4 (Crmp4), cysteine and glycine rich protein 1 (Csrp1), protein Tns 1 (Tns1), and leukocyte elastase inhibitor A (Serpinb1a). Crmp4 has high association with lung [53] cancers. Csrp1 may play a role in lung fibrosis [54] . Several genome wide association studies have identified Tns1 as an important determinant of lung function [55] and have linked this protein to an increased risk for COPD [56] as well as allergy associated asthma [57] . Serpinb1a is a serine protease inhibitor which is secreted into the bronchoalveolar space and has been associated with cystic fibrosis [58] , chronic lung disease of prematurity [59] and sarcoidosis [60] . It is important to note that the results described here are from total lung lysates and the role of cell-specific Trx1 interactions is not known.
While we did find known interactions of Trx1, such as peroxiredoxins, we did not find others such as actin. We believe this could be due to the expression level of the transgene as well as to the innate variability of immunoprecipitation experiments. As expected, we did not find TrxR1 because the Trx1 substrate trap cannot form the necessary intramolecular disulfide bond targeted for reduction by TrxR1 [61] . Collectively, these results indicate that the substrate trap is working as expected in our model.
Hyperoxia-Sensitive Trx1 Interactions
Changes in atmospheric oxygen tension can lead to alterations in cellular morphology and organ development. For example, as seen with mechanical ventilation of premature newborns [62] and in animal models of bronchopulmonary dysplasia (BPD) [29, 63] , excess oxygen disrupts lung development and function. In this study, we have used a wellestablished neonatal mouse model of hyperoxia [64] to identify Trx1 substrates under hyperoxic conditions. High oxygen exposure affects lung development and promotes injury in two critical ways: by increasing oxidative stress and altering the cytoskeleton structure. The prevailing hypothesis of hyperoxia-induced lung injury is that excess oxygen promotes the accumulation of reactive oxygen species and causes oxidation of proteins in several cell survival pathways, which leads to cell death [65, 66] . Our previous work has shown that Trx1 is important for cell survival during hyperoxia [17] . It is well documented that Trx1 translocates to the nucleus during oxidative injury [67] which illustrates the importance of Trx1 in nuclear redox homeostasis. Therefore, it is not surprising that our data showed novel targets of Trx1 that lie in the nucleus, including ATP-dependent RNA helicase DDX3X (Ddx3x), guanine nucleotide-binding protein subunit beta-2-like-1 (Gnb2l1), heterogeneous nuclear ribonuclear protein A3, and 40S ribosomal protein S3a (Rps3a). Studies have shown that hyperoxia causes Trx1 oxidation [17, 68] . This data indicates that the reactive Cys32 of the flag-hTrx1 C35S under high oxygen conditions could be oxidized, which may explain why fewer targets of Trx1 were identified in this cohort.
The cytoskeleton is dynamic and responds to multiple cellular stresses. This structure includes the actin-based cytoskeleton and the tubulin-based myotubules. The flexibility of the cytoskeleton in the lung is necessary for alveolar stretch during respiration [69] . Previous studies have shown that the cytoskeleton is altered in hyperoxic conditions. In particular, excess oxygen stimulates the formation of f-actin, which forms disorganized stress fibers throughout the cell body [70, 71] . Trx1 has been shown to interact with actin and inhibit the formation of stress fibers in response to the oxidant hydrogen peroxide [72, 73] . We identified capping protein (actin filament) muscle, Z-line, beta, isoform CRA (Capzb), a protein that is responsible for capping the barbed end of actin filaments as a possible target of Trx1 [74] . The presence of this capping protein prevents the formation of f-actin, and therefore maintains the pool of g-actin, until f-actin formation is desired. Contact with Capzb may be a secondary way Trx1 can control the formation of f-actin fibers during stress. We also identified two myotubule associated proteins, alpha-centractin (Actr1a) and tubulin beta-4B chain (Tubb4b). Tubb4b has a cysteine, Cys12, which is modified by bis(4fluorbenzyl)trisulfide indicating that it this cysteine could potentially be modified by redox enzymes such as Trx1 [75] . Actr1a is part of the dynactin subunit that has high homology to actin, a known target of Trx1 [76, 77] . Since Trx1 has been shown to be highly involved in cytoskeleton dynamics, we hypothesize that these targets are important in the structural changes induced by hyperoxia.
Conclusions
Here we introduce a novel mouse model to study the interactions of Trx1. This transgenic mouse has conditional expression of a Trx1 substrate trap which stabilizes substrate interactions in vivo which we used for proteomic studies. We identified 41 static and 17 hyperoxic-specific Trx1 interactions in postnatal lung. This is the first study, to our knowledge, to use a direct method to detect and identify Trx1 substrates in vivo. In combination with cell-specific cre drivers, this transgenic mouse is a versatile tool to elucidate Trx1 interactions in vivo and understand the physiological role of redox-dependent Trx1 regulation of thiol switches.
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